

**ASX ANNOUNCEMENT**

**DR BRYCE VISSLER TO CHAIR CELLMID'S SCIENTIFIC ADVISORY BOARD**

- *Dr Bryce Vissel appointed as Chairman of Cellmid's Scientific Advisory Board*
- *Dr Vissel has extensive experience in medical research nationally and internationally and is currently Head of the Neurodegenerative Diseases Group at the Garvan Institute*
- *Dr Vissel will guide Cellmid's ongoing efforts to translate the company's robust science into meaningful patient outcomes, across its portfolio of therapeutic development programs*

**SYDNEY, Tuesday, 7 July 2015: Cellmid Limited (ASX: CDY)** has appointed Dr Bryce Vissel as Chairman of its Scientific Advisory Board. Dr Vissel is currently the Head of the Neurodegenerative Diseases research group at the Garvan Institute of Medical Research as well as Conjoint Senior Lecturer at St Vincent's Clinical School, Faculty of Medicine, University of NSW. Prior to that Dr Vissel worked for a decade at the highly prestigious Salk Institute (La Jolla, California, USA), in the world's leading neuroscience laboratory.

Dr Vissel was recruited by the Garvan Institute to Australia from California's Salk Institute to establish and lead research in brain and spinal cord disorders and repair. Dr Vissel's research has been widely recognised internationally, and he has received a number of awards, including the prestigious Fulbright award, a Liebermann award and a BIOFIRST award. Dr Vissel has published more than 50 peer-reviewed papers, many in top tier journals.

"We are delighted to welcome Dr Vissel as the leader of our Scientific Advisory Board", said CEO of Cellmid, Maria Halasz. "Dr Vissel is a world-class researcher and his outstanding medical research experience will be invaluable in guiding Cellmid's therapeutic development programs toward clinical success" she added.

"Cellmid's sharp focus on midkine underpins a range of therapeutic development programs for the company. This is because manipulating midkine therapeutically offers important potential for treating a range of diseases" said Dr Vissel. "My goal is to help realise this potential so that patients can benefit from the robust science underlying the Company's drug development programs" he added.

"I'm delighted to join the team of this exciting company led by an exceptional senior management team" said Dr Vissel.

End

Contact:

Maria Halasz, CEO, T +612 9221 6830



@mariahalasz

**Cellmid Limited (ASX: CDY)**

Cellmid is a revenue stage Australian biotechnology company with a strong product pipeline. The Company generates revenue through its consumer health business and is also developing innovative novel therapies and diagnostic tests for a number of cancer inflammatory indications. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to the novel target midkine and midkine antagonists globally. The Company's most advanced development programmes involve using its anti-midkine antibodies in addition to commercialising midkine as a biomarker for the early diagnosis and prognosis of cancer. For further information please see [www.cellmid.com.au](http://www.cellmid.com.au).

**Midkine (MK)**

Midkine is a growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, midkine is only present in a disease context, and targeting midkine is not expected to harm normal healthy tissues.

**Investment in life sciences companies**

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.